Please assess the completion status of the following clinical trial:

Trial Title: Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory multiple myeloma following 1 previous line of therapy and, is scheduled by the investigator to be treated with vincristine, adriamycin and dexamethasone standard therapy~* measurable secretory multiple myeloma based on defined criteria~* Karnofsky performance status of \>or = 60%~* fulfils defined laboratory requirements within 14 days before baseline~* if female, the patient is either postmenopausal or surgically sterilised or willing to use an acceptable method of birth control for defined period of time~* if male, the patient agrees to use an acceptable barrier method for contraception for a defined period of time.~Exclusion Criteria:~* More than one previous line of therapy for multiple myeloma~* use of bortezomib in the previous line of therapy and/or received bortezomib in a previous trial~* known allergy or hypersensitivity to bortezomib, boron or mannitol~* peripheral neuropathy or neuropathic pain of grade 2 or higher~* myocardial infarction within 6 months of enrollment or had New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VAD Treatment (Type: ACTIVE_COMPARATOR): vincristine in combination with adriamycin and dexamethasone
- PAD Treatment (Type: EXPERIMENTAL): bortezomib in combination with adriamycin and dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).